SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to recent revenue growth and speculation around a potential crypto treasury strategy, sparking significant after-hours volatility. The community is actively debating the stock's low float and potential for a short squeeze, with some cautioning against chasing the spike. Discussions also include the company's compliance status and potential catalysts for further upward movement.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as the community discusses potential catalysts stemming from activity surrounding the White House's social media, drawing comparisons to the stock's previous surges. Community members are debating the potential impact of this activity and its implications for a possible short squeeze. The stock's movement is also being compared to other meme stocks like BYND, with some suggesting a rotation of interest.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings and potential catalysts like rate cuts and S&P 500 inclusion. The community is closely watching for a breakout above the $30 resistance level, with many expecting a significant move post-earnings. Bullish sentiment is fueled by strong growth metrics and the company's position as a disruptor in the fintech sector.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET is trending following news of a $5 million production order, signaling a move from R&D to commercialization and revenue generation, a key milestone for the company. Community members are discussing the potential for further purchase orders and partnerships, particularly highlighting the connection to Luxshare and Meta, and expecting substantial growth in the AI infrastructure market. While some express concerns about market volatility and dilution, the overall sentiment remains optimistic about POET's long-term prospects in the photonics space.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending amid rumors of a potential acquisition by Novartis ($NVS), sending the stock soaring. The community speculates on the deal's likelihood and potential value, while noting positive clinical data and a strengthened pipeline. Discussions also involve the impact on the broader RNA therapeutics sector and comparisons to other companies in the space.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending as traders discuss the potential for a short squeeze, fueled by high borrow rates and a tightly held float. Community members are actively debating share allocation and the impact of recent insider buying, while closely monitoring short interest data. Sentiment suggests retail investors are optimistic about a potential breakout.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is trending due to the FDA's correction confirming VOQUEZNA's market exclusivity through 2032, driving optimism about the drug's long-term potential. The community is also discussing the upcoming earnings report and potential for a short squeeze, given the high short interest. Bullish sentiment is fueled by strong analyst ratings and the drug's superior profile compared to existing GERD treatments.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene is trending as investors discuss its recovery potential and options activity, with a focus on call options. Community members are weighing the impact of potential healthcare deals and upcoming earnings amid broader market uncertainty. Bullish sentiment seems to be fueled by the prospect of ACA subsidy extensions.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is trending as the community discusses recent price movements and potential trading strategies, particularly around key support levels and upcoming earnings. Bullish sentiment is emerging, with some anticipating a rise toward previous highs, while others focus on the stock's defensive qualities amid market uncertainty. Discussions include long-term holds, dividend payouts, and potential spin-offs to unlock shareholder value.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending as investors discuss its potential acquisition by INCY and compare it to competitor KURA, particularly focusing on the safety profiles of their respective leukemia treatments. Community members are weighing the impact of a recent FDA approval for Syndax's Revuforj against concerns over a "black box" warning, while also evaluating future revenue potential and possible buyout scenarios.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced the launch of Power in the Periphery, a new disease education campaign for healthcare professionals (HCPs) to raise awareness and deepen...

Theravance Biopharma to Present New Analyses Highlighting YUPELRI (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

Theravance Biopharma to Present New Analyses Highlighting YUPELRI (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting Theravance Biopharma to Present New Analyses Highlighting YUPELRI...

Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.

Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of +42.86% and +53.76%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +100.00% and +33.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics

CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises

Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire DUBLIN, Feb. 20, 2025 DUBLIN, Feb. 20, 2025...

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Theravance Biopharma Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

TBPH
Theravance Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TBPH News

TBPHTheravance Biopharma Inc